Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Oncology
Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Summary: This case report highlights the potential effectiveness and safety of a second docetaxel rechallenge as a later-line treatment strategy for patients with mCRPC who are concerned about the high costs of multigene molecular testing and PARP inhibitors, as well as repeated prostate needle biopsy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Atefeh Deris, Mahdi Sohrabi-Haghighat
Summary: Patients with mCRPC are classified into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. Drug-resistant cells may hinder successful outcomes in the latter two groups. To overcome this challenge, a combination of Docetaxel and Abiraterone is proposed to control both the overall cancer cell population and the drug-resistant subpopulation. Evolutionary Game Theory (EGT) is used as a mathematical modeling approach to study the competition and evolution of mCRPC cancer phenotypes.
Article
Urology & Nephrology
Kristine Kreis, Dirk Horenkamp-Sonntag, Udo Schneider, Jan Zeidler, Gerd Glaeske, Lothar Weissbach
Summary: This study examined real-world haematological toxicity, overall survival, and treatment characteristics of docetaxel and cabazitaxel chemotherapy in mCRPC patients. The findings suggest that cabazitaxel treatment poses higher risk of haematological toxicities and shorter survival time, emphasizing the importance of strict indications when using cabazitaxel in mCRPC patients.
Article
Oncology
Eric Feng, Nicholas R. Rydzewski, Meng Zhang, Arian Lundberg, Matthew Bootsma, Kyle T. Helzer, Joshua M. Lang, Rahul Aggarwal, Eric J. Small, David A. Quigley, Martin Sjostrom, Shuang G. Zhao
Summary: In this study, the researchers identified the intrinsic molecular subtypes of metastatic castration-resistant prostate cancer (mCRPC) and assessed their molecular and clinical correlates using a large cohort with gene expression data. The results showed the heterogeneity of mCRPC beyond currently accepted molecular phenotypes, emphasizing the need for transcriptome-wide profiling in future studies to understand the impact of these differences on treatment responses and outcomes.
CLINICAL CANCER RESEARCH
(2022)
Article
Medicine, General & Internal
Oliver Sartor, Johann de Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Alison Armour, Wendy J. Perez-Contreras, Michelle DeSilvio, Euloge Kpamegan, Germo Gericke, Richard A. Messmann, Michael J. Morris, Bernd J. Krause
Summary: The radioligand therapy with Lu-177-PSMA-617 prolonged both imaging-based progression-free survival and overall survival in patients with PSMA-positive metastatic castration-resistant prostate cancer when added to standard care. Adverse events were more common with Lu-177-PSMA-617 but did not significantly impact quality of life.
NEW ENGLAND JOURNAL OF MEDICINE
(2021)
Article
Urology & Nephrology
David Lorente, Casilda Llacer, Rebeca Lozano, Guillermo de Velasco, Nuria Romero-Laorden, Miguel Rodrigo, Angel Sanchez-Iglesias, Carlos di Capua, Elena Castro, Carlos Ferrer, Alfredo Sanchez-Hernandez, David Olmos
Summary: This study validated the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors, showing that low-risk patients received the greatest benefit. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients.
Review
Biochemistry & Molecular Biology
Yasemin Sanli, Duygu Has Simsek, Oner Sanli, Rathan M. Subramaniam, Ayse Tuba Kendi
Summary: Lu-177-PSMA therapy shows promising clinical efficacy in patients with mCRPC, with predictors of efficacy being significant. Ongoing clinical trials, including a phase III multicenter FDA registration trial, are currently being conducted in the United States.
Article
Pharmacology & Pharmacy
Li-Wen Chang, Sheng-Chun Hung, Jian-Ri Li, Kun-Yuan Chiu, Cheng-Kuang Yang, Chuan-Shu Chen, Kevin Lu, Cheng-Che Chen, Shu-Chi Wang, Chia-Yen Lin, Chen-Li Cheng, Yen-Chuan Ou, Shun-Fa Yang, Chiann-Yi Hsu, Szu-Hang Ho, Shian-Shiang Wang
Summary: The study investigated the prognostic efficacy of the Geriatric Nutritional Risk Index (GNRI) in patients with metastatic Castration-resistant Prostate Cancer (mCRPC) receiving docetaxel as the first line of treatment. It was found that poor nutritional status, indicated by a GNRI <92, was associated with shorter progression free survival and overall survival. Additionally, metastatic volume and cumulative docetaxel dosage were identified as independent prognostic factors in overall survival.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Oncology
Sandy Srinivas
Summary: Significant advancements in the management of mCRPC include the development of newer imaging methods utilizing PSMA PET and radionuclide ligands, as well as the use of PARP inhibitors and Cabazitaxel in treatment. Investigators are focusing on sequencing therapies based on previous exposure to optimize treatment choices for mCRPC patients.
JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
(2021)
Article
Oncology
Kim N. Chi, Dana Rathkopf, Matthew R. Smith, Eleni Efstathiou, Gerhardt Attard, David Olmos, Ji Youl Lee, Eric J. Small, Andrea J. Pereira De Santana Gomes, Guilhem Roubaud, Marniza Saad, Bogdan Zurawski, Valerii Sakalo, Gary E. Mason, Peter Francis, George Wang Ms, Daphne Wu, Brooke Diorio, Angela Lopez-Gitlitz, Shahneen Sandhu
Summary: This study investigated the efficacy of niraparib in combination with abiraterone acetate plus prednisone in patients with mCRPC and HRR gene alterations. The results showed that the combination therapy significantly prolonged radiographic progression-free survival compared to abiraterone acetate plus prednisone alone. The treatment was well tolerated with manageable adverse events.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Ciara Conduit, Blossom Mak, Wenjia Qu, Juliana Di Lulio, Ronan Burder, Matthias Bressel, Thomas Cusick, Haryana M. Dhillon, Richard De Abreu Lourenco, Craig Underhill, Javier Torres, Megan Crumbaker, Florian Honeyball, Anthony Linton, Ray Allen, Ian D. Davis, Susan J. Clark, Lisa G. Horvath, Kate L. Mahon
Summary: The study aims to assess the efficacy and safety of intermittent docetaxel chemotherapy guided by circulating mGSTP1 in men with metastatic castration-resistant prostate cancer. It plans to recruit 120 patients for randomised observation and evaluate the utility of mGSTP1 as a biomarker in guiding treatment.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2022)
Review
Cell Biology
Vincenza Conteduca, Alessandra Mosca, Nicole Brighi, Ugo de Giorgi, Pasquale Rescigno
Summary: Prostate cancer is a common cancer in men and patients may develop metastatic disease after radical treatments. Prognostic biomarkers are urgently needed to define patients' risk of cancer-related death.
Article
Oncology
Erik D. Hanson, Mohamdod Alzer, Jackson Carver, Cameron K. Stopforth, Alexander R. Lucas, Young E. Whang, Matthew Milowsky, David B. Bartlett, Michael R. Harrison, Rhonda L. Bitting, Allison M. Deal, Lee Stoner, A. C. Hackney, Claudio L. Battaglini
Summary: The feasibility of a home-based exercise intervention in men with metastatic castration-resistant prostate cancer (mCRPC) was evaluated. The study found that home-based exercise is feasible during ARSI treatment for mCRPC and can improve endurance capacity and localized hypertrophy.
PROSTATE CANCER AND PROSTATIC DISEASES
(2023)
Review
Pharmacology & Pharmacy
Junru Chen, Yaowen Zhang, Xingming Zhang, Jinge Zhao, Yuchao Ni, Sha Zhu, Ben He, Jindong Dai, Zhipeng Wang, Zilin Wang, Jiayu Liang, Xudong Zhu, Pengfei Shen, Hao Zeng, Guangxi Sun
Summary: This study compares the efficacy and safety of systemic treatments in mCRPC patients who have failed docetaxel. The results suggest that enzalutamide may offer the most significant survival benefits and satisfying safety, while cabazitaxel is effective in post-docetaxel settings but associated with a high risk of SAEs.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Petri Reinikainen, Miikka Lehtonen, Ilari Lehtinen, Tiina Luukkaala, Harri Sintonen, Pirkko-Liisa Kellokumpu-Lehtinen
Summary: This prospective study compared the health-related quality of life (HRQoL) of patients with early prostate cancer (PC) treated with radiotherapy (RT) without hormonal treatment to that of the age-standardized general male population. The overall HRQoL of patients was similar to that of the general male population. However, patients experienced more depression at the beginning of RT and had lower sexual activity levels after treatment.
CLINICAL GENITOURINARY CANCER
(2023)
Article
Infectious Diseases
Viivi Nevanlinna, Reetta Huttunen, Janne Aittoniemi, Tiina Luukkaala, Sari Rantala
Summary: This study aimed to investigate the risk factors associated with S. dysgalactiae subsp. equisimilis bacteremia. Using the Finhealth study data in Finland, it was found that obesity, diabetes, and coronary artery disease were associated with an increased risk of S. dysgalactiae subsp. equisimilis bacteremia.
BMC INFECTIOUS DISEASES
(2023)
Article
Oncology
Margaret A. Tempero, Uwe Pelzer, Eileen M. O'Reilly, Jordan Winter, Do-Youn Oh, Chung-Pin Li, Giampaolo Tortora, Heung-Moon Chang, Charles D. Lopez, Tanios Bekaii-Saab, Andrew H. Ko, Armando Santoro, Joon Oh Park, Marcus S. Noel, Giovanni Luca Frassineti, Yan-Shen Shan, Andrew Dean, Hanno Riess, Eric Van Cutsem, Jordan Berlin, Philip Philip, Malcolm Moore, David Goldstein, Josep Tabernero, Mingyu Li, Stefano Ferrara, Yvan Le Bruchec, George Zhang, Brian Lu, Andrew V. Biankin, Michele Reni
Summary: In this randomized, open-label trial, adjuvant nab-paclitaxel + gemcitabine was compared with gemcitabine alone for resected pancreatic ductal adenocarcinoma. The study found that although nab-paclitaxel + gemcitabine showed favorable overall survival, it did not meet the primary endpoint of independently assessed disease-free survival.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Review
Oncology
Mary O'Reilly, Anna Linehan, Aleksandar Krstic, Walter Kolch, Kieran Sheahan, Des C. Winter, Ray Mc Dermott
Summary: Early onset colorectal cancer (EOCRC), defined as colorectal cancers in patients aged less than 50 years, is becoming an increasingly common issue globally. The incidence of EOCRC has been rising by 2% annually since 1994. Patients with EOCRC have distinct social, spiritual, fertility, and financial needs that need to be addressed. This review discusses the risk factors and management strategies for EOCRC.
Article
Infectious Diseases
Viivi Nevanlinna, Reetta Huttunen, Janne Aittoniemi, Tiina Luukkaala, Sari Rantala
Summary: This study investigated the incidence, seasonal pattern, clinical manifestations, and recurrence of Streptococcus dysgalactiae subspecies equisimilis (SDSE) bacteremia. A total of 217 episodes (involving 211 patients) were analyzed, with an average annual incidence rate of 16.9/100,000 inhabitants. The majority of episodes (33%) occurred during the summer, and bacteremic cellulitis was more common in the summer compared to other seasons. Cellulitis was the most common clinical manifestation of SDSE bacteremia.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES
(2023)
Article
Urology & Nephrology
Wassim Abida, David Campbell, Akash Patnaik, Alan H. Bryce, Jeremy Shapiro, Richard M. Bambury, Jingsong Zhang, John M. Burke, Daniel Castellano, Albert Font, Vinod Ganju, Anne-Claire Hardy-Bessard, Ray McDermott, Brieuc Sautois, Dominique Spaeth, Eric Voog, Josep M. Piulats, Elias Pintus, Charles J. Ryan, Axel S. Merseburger, Gedske Daugaard, Axel Heidenreich, Karim Fizazi, Andrea Loehry, Darrin Despain, Andrew D. Simmons, Melanie Dowsonz, Jowell Goy, Simon P. Watkinsz, Simon Chowdhury
Summary: The final data from TRITON2 confirms the clinical benefit and manageable safety profile of rucaparib in patients with metastatic castration-resistant prostate cancer (mCRPC), particularly those with BRCA or other non-BRCA DNA damage repair gene alterations.
Editorial Material
Oncology
Dean F. Bajorin, J. Alfred Witjes, Juergen E. Gschwend, Michael Schenker, Begona P. Valderrama, Yoshihiko Tomita, Aristotelis Bamias, Thierry Lebret, Shahrokh F. Shariat, Se Hoon Park, Dingwei Ye, Mads Agerbaek, Deborah Enting, Ray McDermott, Pablo Gajate, Avivit Peer, Matthew Milowsky, Alexander Nosov, Joao Neif Antonio Jr, Krzysztof Tupikowski, Laurence Toms, Bruce S. Fischer, Anila Qureshi, Sandra Collette, Keziban Unsal-Kacmaz, Edward Broughton, Dimitrios Zardavas, Henry B. Koon, Matthew D. Galsky
Article
Oncology
Emmanuel S. Antonarakis, Se Hoon Park, Jeffrey C. Goh, Sang Joon Shin, Jae Lyun Lee, Niven Mehra, Ray McDermott, Nuria Sala-Gonzalez, Peter C. Fong, Richard Greil, Margitta Retz, Juan Pablo Sade, Patricio Yanez, Yi-Hsiu Huang, Stephen D. Begbie, Rustem Airatovich Gafanov, Maria De Santis, Eli Rosenbaum, Michael P. Kolinsky, Felipe Rey, Kun-Yuan Chiu, Guilhem Roubaud, Gero Kramer, Makoto Sumitomo, Francesco Massari, Hiroyoshi Suzuki, Ping Qiu, Jinchun Zhang, Jeri Kim, Christian H. Poehlein, Evan Y. Yu
Summary: This study evaluated the efficacy of pembrolizumab plus olaparib compared to a next-generation hormonal agent (NHA) for heavily pretreated mCRPC patients. The results showed that pembrolizumab plus olaparib did not significantly improve rPFS or OS. The study was stopped for futility and no new safety signals were observed.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S. Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klumpen, Stephen L. Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W. Valle, Li Yu, Usha Malhotra, Abby B. Siegel, Julien Edeline, Arndt Vogel
Summary: This study examined the efficacy of adding the immune checkpoint inhibitor pembrolizumab to the standard chemotherapy regimen for advanced biliary tract cancer. The results showed that the combination treatment significantly improved overall survival compared to chemotherapy alone.
Article
Medicine, General & Internal
Karim Fizazi, Josep M. Piulats, M. Neil Reaume, Peter Ostler, Ray McDermott, Joel R. Gingerich, Elias Pintus, Srikala S. Sridhar, Richard M. Bambury, Urban Emmenegger, Henriette Lindberg, David Morris, Franco Nole, John Staffurth, Charles Redfern, Maria I. Saez, Wassim Abida, Gedske Daugaard, Axel Heidenreich, Laurence Krieger, Brieuc Sautois, Andrea Loehr, Darrin Despain, Catherine A. Heyes, Simon P. Watkins, Simon Chowdhury, Charles J. Ryan, Alan H. Bryce
Summary: In this Phase 3 trial, the PARP inhibitor rucaparib demonstrated significant activity in patients with metastatic, castration-resistant prostate cancer with a deleterious BRCA alteration. The duration of imaging-based progression-free survival was significantly prolonged in the rucaparib group compared to the control group.
NEW ENGLAND JOURNAL OF MEDICINE
(2023)
Article
Oncology
Grainne Sheill, Lauren Brady, Brian Hayes, Anne-Marie Baird, Emer Guinan, Rishabh Vishwakarma, Caroline Brophy, Tatjana Vlajnic, Orla Casey, Verena Murphy, John Greene, Emma Allott, Juliette Hussey, Fidelma Cahill, Mieke Van Hemelrijck, Nicola Peat, Lorelei Mucci, Moya Cunningham, Liam Grogan, Thomas Lynch, Rustom P. Manecksha, John McCaffrey, Dearbhaile O'Donnell, Orla Sheils, John O'Leary, Sarah Rudman, Ray McDermott, Stephen Finn
Summary: This paper examines the impact of a 6-month aerobic exercise intervention on secondary endpoints in men with metastatic prostate cancer. The results show that the intervention did not lead to changes in quality of life for patients with a high burden of metastatic disease. Further research is needed to understand the role of exercise for people living with metastatic prostate cancer.
SUPPORTIVE CARE IN CANCER
(2023)
Article
Physiology
Akseli Laaksi, Ilkka Laaksi, Harri Pihlajamaki, Jani P. Vaara, Tiina Luukkaala, Heikki Kyrolainen
Summary: The present study examined the association of serum 25(OH)D levels with physical performance outcomes and serum levels of anabolic hormones in young men. The results showed a positive association between serum 25(OH)D levels and both aerobic and muscular fitness. Participants with sufficient levels of vitamin D also had higher levels of testosterone. Maintaining a sufficient serum 25(OH)D level may have beneficial effects on physical performance and anabolic state in young men.
FRONTIERS IN PHYSIOLOGY
(2023)
Article
Urology & Nephrology
Elizabeth R. Plimack, Thomas Powles, Viktor Stus, Rustem Gafanov, Dmitry Nosov, Tom Waddell, Boris Alekseev, Frederic Pouliot, Bohuslav Melichar, Denis Soulieres, Delphine Borchiellini, Raymond S. Mcdermott, Ihor Vynnychenko, Yen-Hwa Chang, Satoshi Tamada, Michael B. Atkins, Chenxiang Li, Rodolfo Perini, L. Rhoda Molife, Jens Bedke, Brian I. Rini
Summary: This study reports the efficacy of pembrolizumab plus axitinib in patients with advanced clear cell renal cell carcinoma. Compared to the traditional treatment, pembrolizumab plus axitinib showed superior outcomes in overall survival, progression-free survival, and objective response rate.
Review
Cardiac & Cardiovascular Systems
Gillian Murtagh, James L. Januzzi, Marielle Scherrer-Crosbie, Tomas G. Neilan, Susan Dent, Jennifer E. Ho, Vinesh Appadurai, Ray McDermott, Nausheen Akhter
Summary: Cardiotoxicity is a growing concern in the oncology population. Current imaging techniques for surveillance are relatively insensitive and resource intensive, highlighting the need for more sensitive and cost-effective strategies. Circulating cardiovascular biomarkers offer a promising solution, but there are limitations to their use. This review discusses the challenges in biomarker measurement and interpretation, and suggests improved study designs and harmonization efforts to enhance their predictive value.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Review
Medicine, General & Internal
Miikka Lehtonen, Pirkko-Liisa Kellokumpu-Lehtinen
Summary: The prognosis of local and metastatic prostate cancer has significantly improved in the past 60 years. New pharmaceuticals and treatment options have been introduced, including robotic-assisted radical prostatectomy, stereotactic radiotherapy, and brachytherapy. Chemotherapeutic and androgen-suppressive treatments, as well as diagnostic imaging and staging, have also improved. This review provides a concise overview of the history of prostate cancer treatment and diagnostics, aiming to be accessible to healthcare professionals and patients.
SAGE OPEN MEDICINE
(2023)